PYC Therapeutics Limited (ASX: PYC)
Australia
· Delayed Price · Currency is AUD 0.190
0.00 (0.00%)
Nov 14, 2024, 4:10 PM AEST
PYC Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Other Revenue | 22.06 | 22.06 | 15.81 | 16.04 | 3.07 | 2.4 | Upgrade
|
| Revenue | 22.06 | 22.06 | 15.81 | 16.04 | 3.07 | 2.4 | Upgrade
|
| Revenue Growth (YoY) | 39.56% | 39.56% | -1.47% | 421.83% | 28.33% | - | Upgrade
|
| Cost of Revenue | - | - | - | - | - | 0.03 | Upgrade
|
| Gross Profit | 22.06 | 22.06 | 15.81 | 16.04 | 3.07 | 2.36 | Upgrade
|
| Selling, General & Admin | 4.51 | 4.51 | 4.09 | 6.3 | 7.83 | 3.82 | Upgrade
|
| Research & Development | 56.41 | 56.41 | 35.15 | 24.03 | 14 | 5.85 | Upgrade
|
| Operating Expenses | 60.92 | 60.92 | 39.24 | 30.33 | 21.83 | 9.67 | Upgrade
|
| Operating Income | -38.86 | -38.86 | -23.43 | -14.29 | -18.76 | -7.31 | Upgrade
|
| Interest Expense | -0.05 | -0.05 | -0.03 | -0.03 | -0.04 | -0.04 | Upgrade
|
| Interest & Investment Income | 0.8 | 0.8 | 0.08 | 0.02 | 0.11 | 0.21 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 0 | - | Upgrade
|
| EBT Excluding Unusual Items | -38.11 | -38.11 | -23.38 | -14.29 | -18.69 | -7.14 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.02 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.06 | 0.06 | Upgrade
|
| Pretax Income | -38.11 | -38.11 | -23.36 | -14.29 | -18.63 | -7.08 | Upgrade
|
| Earnings From Continuing Operations | -38.11 | -38.11 | -23.36 | -14.29 | -18.63 | -7.08 | Upgrade
|
| Minority Interest in Earnings | 0.39 | 0.39 | 0.57 | 0.43 | 0.86 | 0.26 | Upgrade
|
| Net Income | -37.73 | -37.73 | -22.79 | -13.86 | -17.77 | -6.82 | Upgrade
|
| Net Income to Common | -37.73 | -37.73 | -22.79 | -13.86 | -17.77 | -6.82 | Upgrade
|
| Shares Outstanding (Basic) | 394 | 394 | 321 | 318 | 309 | 275 | Upgrade
|
| Shares Outstanding (Diluted) | 394 | 394 | 321 | 318 | 309 | 275 | Upgrade
|
| Shares Change (YoY) | 22.59% | 22.59% | 0.93% | 2.89% | 12.58% | 17.18% | Upgrade
|
| EPS (Basic) | -0.10 | -0.10 | -0.07 | -0.04 | -0.06 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.10 | -0.10 | -0.07 | -0.04 | -0.06 | -0.02 | Upgrade
|
| Free Cash Flow | -38.9 | -38.9 | -24.91 | -22.17 | -12.38 | -5.85 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | -0.10 | -0.08 | -0.07 | -0.04 | -0.02 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 98.70% | Upgrade
|
| Operating Margin | -176.15% | -176.15% | -148.24% | -89.05% | -610.16% | -304.97% | Upgrade
|
| Profit Margin | -171.02% | -171.02% | -144.18% | -86.41% | -577.93% | -284.77% | Upgrade
|
| Free Cash Flow Margin | -176.32% | -176.32% | -157.61% | -138.19% | -402.76% | -244.37% | Upgrade
|
| EBITDA | -38.12 | -38.12 | -22.8 | -13.69 | -18.33 | -6.92 | Upgrade
|
| EBITDA Margin | -172.80% | -172.80% | -144.25% | -85.31% | - | -288.98% | Upgrade
|
| D&A For EBITDA | 0.74 | 0.74 | 0.63 | 0.6 | 0.42 | 0.38 | Upgrade
|
| EBIT | -38.86 | -38.86 | -23.43 | -14.29 | -18.76 | -7.31 | Upgrade
|
| EBIT Margin | -176.15% | -176.15% | -148.24% | -89.05% | - | - | Upgrade
|
| Revenue as Reported | 22.86 | 22.86 | 15.91 | 16.07 | 3.24 | 2.67 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.